Results | In total, 208 SPUs were approved, and the product was administered in 185 instances to 179 patients (mean [SD] Twenty-six patients received therapy in a minimal residual disease state or remission and were thus not assessed for response. Of the remaining 159 patients with evaluable data, the overall response rate was 20.1% (95% CI, 14.2%-27.2%). Best response varied by patient and product characteristics (Figure 1 ). Responses occurred with a variety of agent types, most commonly kinase inhibitors (9 [16.7%]), allogeneic cell therapy (3 [17.6%]), and antibody drug conjugates (1 [5.3%]). Estimated progression-free survival rates were 38.9% (95% CI, 31.6%-46.1%) at 6 months and 24.5% (95% CI, 18.2%-31.4%) at 1 year ( Figure 2A) . Median overall survival was 11.4 months (95% CI, 8.7-18.9 months) ( Figure 2B ). Median follow-up for survivors was 16 months (range, 0-71 months).
A total of 55 of 185 patients (29.7%) experienced 1 or more treatment-related serious adverse event (12 [19.1%] in pediatric patients, 43 [35.3%] in adults). There were no treatmentrelated deaths.
Discussion | The FDA Expanded Access program provided access to investigational products at all stages of development and to patients of all ages with a variety of cancer types. Despite being heavily pretreated, a small but meaningful proportion of patients appeared to benefit. Children represented 34.1% of the cohort despite being only approximately 2% of the patients seen at the center in 2017, suggesting SPUs may provide an important means of pediatric drug access.
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Our study has some important limitations. It was conducted at a single academic cancer center, and the retrospective design precluded the collection of certain data elements. Moreover, although the federal Right-to-Try law promises to further expand prescribing of unapproved products, differences in the precise requirements and implementation of this new access mechanism may make aspects of our current SPU analysis only partially applicable. 3, 4, 6 In summary, our data provide an initial evidence basis to evaluate the FDA Expanded Access mechanism. We find its use is broad, involving a wide variety of patients and products, and clinical benefit was observed. Routine prospective collection of key safety and efficacy metrics should be considered moving forward. 
